Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Pharmacol. 2014 Mar;171(5):1231-40. doi: 10.1111/bph.12526.

Should pharmacologists care about alternative splicing? IUPHAR Review 4.

Author information

  • 1National Institute of Mental Health, Bethesda, MD, USA.

Abstract

Alternative splicing of mRNAs occurs in the majority of human genes, and most differential splicing results in different protein isoforms with possibly different functional properties. However, there are many reported splicing variations that may be quite rare, and not all combinatorially possible variants of a given gene are expressed at significant levels. Genes of interest to pharmacologists are frequently expressed at such low levels that they are not adequately represented in genome-wide studies of transcription. In single-gene studies, data are commonly available on the relative abundance and functional significance of individual alternatively spliced exons, but there are rarely data that quantitate the relative abundance of full-length transcripts and define which combinations of exons are significant. A number of criteria for judging the significance of splice variants and suggestions for their nomenclature are discussed.

KEYWORDS:

5-HT4 receptor; CaV1.2; CaV3.1; PAC1 receptor; alternative splicing; splice variant nomenclature

PMID:
24670145
PMCID:
PMC3952800
DOI:
10.1111/bph.12526
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center